Across TCGA pan-cancer cohorts, ZBED1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZBED1 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ZBED1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ZBED1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, CCRCC, and PDAC are the cancer types where ZBED1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	IV	0.918	0.688	.034	5	view →
CCRCC	DFS	Tertile	II,III,IV	1.000	0.496	.024	5	view →
PDAC	OS	Quartile	All	0.883	0.674	.022	5	view →
LUAD	DFS	Tertile	II,III,IV	0.861	0.256	.024	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ZBED1 tumor-vs-normal RNA expression · all ZBED1 data types